Trial Outcomes & Findings for Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (NCT NCT02948829)
NCT ID: NCT02948829
Last Updated: 2024-03-15
Results Overview
Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
200 participants
Primary outcome timeframe
1 month post second vaccination (Day 120)
Results posted on
2024-03-15
Participant Flow
Participants took part in the study at 2 investigative sites in Panama and Philippines from 03 April 2017 to 14 December 2020.
Healthy participants were enrolled in a single arm in this study to receive 2 doses of Tetravalent Dengue Vaccine (TDV) injection subcutaneously (SC).
Participant milestones
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
|---|---|
|
Overall Study
STARTED
|
200
|
|
Overall Study
COMPLETED
|
184
|
|
Overall Study
NOT COMPLETED
|
16
|
Reasons for withdrawal
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
|---|---|
|
Overall Study
Lost to Follow-up
|
2
|
|
Overall Study
Withdrawal by Subject and/or Subject's Parent(s)/ Legally Authorized Representative (LAR)
|
5
|
|
Overall Study
Pregnancy
|
1
|
|
Overall Study
Other: Reason not Specified
|
8
|
Baseline Characteristics
Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Baseline characteristics by cohort
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
|---|---|
|
Age, Continuous
|
6.7 years
STANDARD_DEVIATION 2.28 • n=5 Participants
|
|
Sex: Female, Male
Female
|
101 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
99 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
99 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
101 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
76 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
100 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
8 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
9 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
7 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
Panama
|
100 Participants
n=5 Participants
|
|
Region of Enrollment
Philippines
|
100 Participants
n=5 Participants
|
|
Height
|
118.38 cm
STANDARD_DEVIATION 14.564 • n=5 Participants
|
|
Weight
|
23.54 kg
STANDARD_DEVIATION 10.258 • n=5 Participants
|
|
Body Mass Index (BMI)
|
16.15 kg/m^2
STANDARD_DEVIATION 3.104 • n=5 Participants
|
|
Baseline Seropositivity Status
Seropositive
|
113 Participants
n=5 Participants
|
|
Baseline Seropositivity Status
Seronegative
|
87 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 1 month post second vaccination (Day 120)Population: Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.
Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=173 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination
|
97.1 percentage of participants
Interval 93.4 to 99.1
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post second vaccination (Day 120)Population: PPS included all participants from the FAS who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.
The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=168 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination
|
846.5 SFC/million PBMCs
Interval 378.5 to 1968.5
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=195 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 30
|
95.3 percentage of participants
Interval 91.0 to 98.0
|
—
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 90
|
95.1 percentage of participants
Interval 90.9 to 97.7
|
—
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 270
|
95.4 percentage of participants
Interval 91.1 to 98.0
|
—
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 1
|
90.8 percentage of participants
Interval 85.5 to 94.7
|
—
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 2
|
84.0 percentage of participants
Interval 77.1 to 89.5
|
—
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 3
|
77.8 percentage of participants
Interval 70.8 to 83.8
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=195 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 30
|
1019.0 SFC/million PBMCs
Interval 418.0 to 2542.0
|
—
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 90
|
536.5 SFC/million PBMCs
Interval 254.0 to 1212.0
|
—
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Day 270
|
486.0 SFC/million PBMCs
Interval 203.0 to 1252.0
|
—
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 1
|
193.0 SFC/million PBMCs
Interval 76.0 to 482.0
|
—
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 2
|
104.0 SFC/million PBMCs
Interval 41.0 to 560.0
|
—
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
Year 3
|
136.0 SFC/million PBMCs
Interval 47.0 to 577.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3Population: PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=97 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=98 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Day 30
|
96.1 percentage of participants
Interval 88.9 to 99.2
|
94.7 percentage of participants
Interval 88.1 to 98.3
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Day 90
|
96.5 percentage of participants
Interval 90.0 to 99.3
|
93.9 percentage of participants
Interval 87.1 to 97.7
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Day 120
|
97.3 percentage of participants
Interval 90.7 to 99.7
|
96.9 percentage of participants
Interval 91.3 to 99.4
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Day 270
|
94.7 percentage of participants
Interval 86.9 to 98.5
|
95.9 percentage of participants
Interval 89.9 to 98.9
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Year 1
|
91.6 percentage of participants
Interval 83.4 to 96.5
|
90.1 percentage of participants
Interval 82.1 to 95.4
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Year 2
|
86.5 percentage of participants
Interval 74.2 to 94.4
|
82.7 percentage of participants
Interval 73.7 to 89.6
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
Year 3
|
79.7 percentage of participants
Interval 69.2 to 88.0
|
76.1 percentage of participants
Interval 66.1 to 84.4
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). Percentages are rounded off to the nearest decimal point.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=109 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=86 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Day 30
|
91.8 percentage of participants
Interval 84.4 to 96.4
|
100.0 percentage of participants
Interval 95.1 to 100.0
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Day 90
|
93.3 percentage of participants
Interval 86.6 to 97.3
|
97.5 percentage of participants
Interval 91.2 to 99.7
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Day 120
|
96.0 percentage of participants
Interval 90.1 to 98.9
|
98.6 percentage of participants
Interval 92.6 to 100.0
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Day 270
|
93.1 percentage of participants
Interval 86.2 to 97.2
|
98.6 percentage of participants
Interval 92.5 to 100.0
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Year 1
|
87.8 percentage of participants
Interval 79.6 to 93.5
|
94.7 percentage of participants
Interval 87.1 to 98.5
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Year 2
|
80.6 percentage of participants
Interval 71.1 to 88.1
|
89.5 percentage of participants
Interval 78.5 to 96.0
|
—
|
—
|
|
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
Year 3
|
74.2 percentage of participants
Interval 64.3 to 82.6
|
82.4 percentage of participants
Interval 71.8 to 90.3
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.
The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=97 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=98 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Day 30
|
1019.0 SFC/million PBMCs
Interval 437.0 to 2228.0
|
1065.0 SFC/million PBMCs
Interval 418.0 to 2546.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Day 90
|
531.5 SFC/million PBMCs
Interval 252.0 to 1116.0
|
577.5 SFC/million PBMCs
Interval 255.5 to 1396.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Day 120
|
780.0 SFC/million PBMCs
Interval 322.0 to 1525.0
|
1003.0 SFC/million PBMCs
Interval 437.0 to 2304.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Day 270
|
426.0 SFC/million PBMCs
Interval 184.0 to 1382.0
|
512.5 SFC/million PBMCs
Interval 210.0 to 1130.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Year 1
|
209.0 SFC/million PBMCs
Interval 81.5 to 494.0
|
178.5 SFC/million PBMCs
Interval 73.0 to 451.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Year 2
|
76.0 SFC/million PBMCs
Interval 45.0 to 229.0
|
124.0 SFC/million PBMCs
Interval 41.0 to 615.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
Year 3
|
147.0 SFC/million PBMCs
Interval 51.0 to 280.0
|
117.0 SFC/million PBMCs
Interval 43.0 to 659.0
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=109 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=86 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Day 30
|
1415.0 SFC/million PBMCs
Interval 529.0 to 3302.0
|
840.5 SFC/million PBMCs
Interval 379.0 to 1844.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Day 90
|
743.0 SFC/million PBMCs
Interval 257.0 to 1560.0
|
473.0 SFC/million PBMCs
Interval 246.0 to 927.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Day 120
|
1086.0 SFC/million PBMCs
Interval 429.0 to 2521.0
|
700.0 SFC/million PBMCs
Interval 343.0 to 1476.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Day 270
|
592.5 SFC/million PBMCs
Interval 184.0 to 1569.0
|
400.0 SFC/million PBMCs
Interval 225.0 to 808.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Year 1
|
275.0 SFC/million PBMCs
Interval 105.0 to 690.0
|
132.0 SFC/million PBMCs
Interval 69.0 to 247.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Year 2
|
135.0 SFC/million PBMCs
Interval 46.0 to 615.0
|
74.0 SFC/million PBMCs
Interval 38.0 to 304.0
|
—
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
Year 3
|
180.0 SFC/million PBMCs
Interval 61.0 to 645.5
|
103.0 SFC/million PBMCs
Interval 35.0 to 430.0
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 14Population: PPS with participants \>10 years of age included all participants from the FAS who have no major protocol violations and are \>10 years of age. The overall number of participants analyzed are the number of participants with data available for analysis at the given timepoint.
Percentage of participants with cellular immune response in participants \>10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=10 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age
|
70.0 percentage of participants
Interval 34.8 to 93.3
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 14Population: PPS with participants \>10 years of age included all participants from the FAS who have no major protocol violations and are \>10 years of age. The overall number of participants analyzed are the number of participants with data available for analysis at the given timepoint.
The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. SFC/million PBMC for any peptide pool is reported in participants \>10 years of age.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=7 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age
|
227.0 SFC/million PBMCs
Interval 124.0 to 3781.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: ICS Subset 'by T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.
The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=79 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=79 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.000080 percentage of T cells
Interval 0.0 to 0.00176
|
0.014120 percentage of T cells
Interval 0.0047 to 0.059078
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.003405
|
0.003625 percentage of T cells
Interval 0.00166 to 0.007235
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000060 percentage of T cells
Interval 0.0 to 0.00139
|
0.000000 percentage of T cells
Interval 0.0 to 0.000647
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.000122 percentage of T cells
Interval 0.0 to 0.002741
|
0.000000 percentage of T cells
Interval 0.0 to 0.000905
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000160 percentage of T cells
Interval 0.0 to 0.00199
|
0.000000 percentage of T cells
Interval 0.0 to 0.00267
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.001000 percentage of T cells
Interval 0.0 to 0.003
|
0.000000 percentage of T cells
Interval 0.0 to 0.00098
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.002000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.00106
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3
|
0.000048 percentage of T cells
Interval 0.0 to 0.00148
|
0.000000 percentage of T cells
Interval 0.0 to 0.00225
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.002908 percentage of T cells
Interval 0.000285 to 0.006325
|
0.005565 percentage of T cells
Interval 0.00147 to 0.0125
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.002050 percentage of T cells
Interval 0.0 to 0.00569
|
0.004020 percentage of T cells
Interval 0.000622 to 0.013
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000615 percentage of T cells
Interval 0.0 to 0.00146
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.0022
|
0.000000 percentage of T cells
Interval 0.0 to 0.001566
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00098
|
0.000000 percentage of T cells
Interval 0.0 to 0.001865
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.001045 percentage of T cells
Interval 0.0 to 0.002805
|
0.005155 percentage of T cells
Interval 0.00002 to 0.02116
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.001608 percentage of T cells
Interval 0.0 to 0.003055
|
0.106350 percentage of T cells
Interval 0.032245 to 0.198546
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.000750 percentage of T cells
Interval 0.0 to 0.002583
|
0.076145 percentage of T cells
Interval 0.0175 to 0.15685
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.001050 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.000884
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.000910 percentage of T cells
Interval 0.0 to 0.00336
|
0.000000 percentage of T cells
Interval 0.0 to 0.00034
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.002925 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.000374
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.001425
|
0.001820 percentage of T cells
Interval 0.0 to 0.006305
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.000973
|
0.022310 percentage of T cells
Interval 0.00758 to 0.075184
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.001251
|
0.021455 percentage of T cells
Interval 0.002945 to 0.045665
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.001500 percentage of T cells
Interval 0.0 to 0.01
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.003000 percentage of T cells
Interval 0.0 to 0.0105
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.0095
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.0285
|
0.012000 percentage of T cells
Interval 0.0005 to 0.03247
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.009500 percentage of T cells
Interval 0.0 to 0.05
|
0.008500 percentage of T cells
Interval 0.0 to 0.0265
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.008340 percentage of T cells
Interval 0.00334 to 0.017
|
0.001320 percentage of T cells
Interval 0.0 to 0.00424
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.003410 percentage of T cells
Interval 0.001041 to 0.00719
|
0.010000 percentage of T cells
Interval 0.00265 to 0.018
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.002100 percentage of T cells
Interval 0.0 to 0.00471
|
0.007850 percentage of T cells
Interval 0.00223 to 0.027
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.001050 percentage of T cells
Interval 0.0 to 0.00242
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.00142
|
0.000000 percentage of T cells
Interval 0.0 to 0.0018
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.000935
|
0.000960 percentage of T cells
Interval 0.0 to 0.00234
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.002110 percentage of T cells
Interval 0.0 to 0.00507
|
0.007340 percentage of T cells
Interval 0.0 to 0.02985
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.002000 percentage of T cells
Interval 0.0 to 0.00416
|
0.116110 percentage of T cells
Interval 0.047 to 0.317
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.000860 percentage of T cells
Interval 0.0 to 0.00282
|
0.096230 percentage of T cells
Interval 0.03005 to 0.20709
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.007160 percentage of T cells
Interval 0.002 to 0.01504
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.00471
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.003350 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120
|
0.002070 percentage of T cells
Interval 0.0 to 0.00503
|
0.004080 percentage of T cells
Interval 0.0 to 0.011
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120
|
0.000990 percentage of T cells
Interval 0.0 to 0.00263
|
0.038000 percentage of T cells
Interval 0.01327 to 0.09481
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.00248
|
0.018850 percentage of T cells
Interval 0.007 to 0.06056
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.009000 percentage of T cells
Interval 0.0 to 0.014
|
0.002000 percentage of T cells
Interval 0.0 to 0.014
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.001000 percentage of T cells
Interval 0.0 to 0.01
|
0.001000 percentage of T cells
Interval 0.0 to 0.017
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.001000 percentage of T cells
Interval 0.0 to 0.015
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.002000 percentage of T cells
Interval 0.0 to 0.028
|
0.004000 percentage of T cells
Interval 0.0 to 0.02
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.03
|
0.012000 percentage of T cells
Interval 0.0 to 0.028
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.020000 percentage of T cells
Interval 0.0 to 0.05
|
0.012000 percentage of T cells
Interval 0.0 to 0.03
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.006150 percentage of T cells
Interval 0.00294 to 0.015
|
0.000000 percentage of T cells
Interval 0.0 to 0.00245
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.002520 percentage of T cells
Interval 0.00005 to 0.00657
|
0.004630 percentage of T cells
Interval 0.00143 to 0.010157
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.002840 percentage of T cells
Interval 0.00022 to 0.00523
|
0.004430 percentage of T cells
Interval 0.000955 to 0.019
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00098
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00183
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00147
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.001100 percentage of T cells
Interval 0.0 to 0.00338
|
0.004620 percentage of T cells
Interval 0.0 to 0.02395
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.001210 percentage of T cells
Interval 0.0 to 0.00345
|
0.089000 percentage of T cells
Interval 0.033 to 0.21391
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.000334 percentage of T cells
Interval 0.0 to 0.0025
|
0.067000 percentage of T cells
Interval 0.021 to 0.19796
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.004010 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00483
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.001630 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00257
|
0.003060 percentage of T cells
Interval 0.0 to 0.00845
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00172
|
0.015360 percentage of T cells
Interval 0.00244 to 0.02994
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00232
|
0.013000 percentage of T cells
Interval 0.002 to 0.0296
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.001000 percentage of T cells
Interval 0.0 to 0.008
|
0.001000 percentage of T cells
Interval 0.0 to 0.007
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00198
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.014
|
0.002000 percentage of T cells
Interval 0.0 to 0.018
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.005000 percentage of T cells
Interval 0.0 to 0.03
|
0.015000 percentage of T cells
Interval 0.0 to 0.044
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.05
|
0.014000 percentage of T cells
Interval 0.0 to 0.033
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00137
|
0.000000 percentage of T cells
Interval 0.0 to 0.000828
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.003980 percentage of T cells
Interval 0.0 to 0.00747
|
0.000000 percentage of T cells
Interval 0.0 to 0.00141
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.001998 percentage of T cells
Interval 0.0 to 0.005
|
0.001360 percentage of T cells
Interval 0.0 to 0.00397
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.001275 percentage of T cells
Interval 0.0 to 0.0059
|
0.001600 percentage of T cells
Interval 0.0 to 0.00666
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000105 percentage of T cells
Interval 0.0 to 0.0017
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00124
|
0.000000 percentage of T cells
Interval 0.0 to 0.00112
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.001085 percentage of T cells
Interval 0.0 to 0.003
|
0.000000 percentage of T cells
Interval 0.0 to 0.012
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.001100 percentage of T cells
Interval 0.0 to 0.002718
|
0.022915 percentage of T cells
Interval 0.00479 to 0.05475
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.000856 percentage of T cells
Interval 0.0 to 0.003
|
0.022135 percentage of T cells
Interval 0.00201 to 0.06986
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.003000 percentage of T cells
Interval 0.0 to 0.009125
|
0.000000 percentage of T cells
Interval 0.0 to 0.00113
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.001585 percentage of T cells
Interval 0.0 to 0.00547
|
0.000000 percentage of T cells
Interval 0.0 to 0.000968
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.003545 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.00137
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1
|
0.000587 percentage of T cells
Interval 0.0 to 0.00258
|
0.000434 percentage of T cells
Interval 0.0 to 0.0052
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.003075 percentage of T cells
Interval 0.0 to 0.01087
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00188
|
0.003400 percentage of T cells
Interval 0.0 to 0.01664
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000500 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.003500 percentage of T cells
Interval 0.0 to 0.018
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.002500 percentage of T cells
Interval 0.0 to 0.06
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.07
|
0.005210 percentage of T cells
Interval 0.0 to 0.022
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.042500 percentage of T cells
Interval 0.0 to 0.12
|
0.007000 percentage of T cells
Interval 0.0 to 0.02025
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.002920 percentage of T cells
Interval 0.00014 to 0.00689
|
0.000000 percentage of T cells
Interval 0.0 to 0.00105
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.000727 percentage of T cells
Interval 0.0 to 0.003915
|
0.001925 percentage of T cells
Interval 0.0 to 0.004043
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.001500 percentage of T cells
Interval 0.0 to 0.005815
|
0.001535 percentage of T cells
Interval 0.0 to 0.005245
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.00104
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.000853
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.001435
|
0.000000 percentage of T cells
Interval 0.0 to 0.000982
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.000871 percentage of T cells
Interval 0.0 to 0.002065
|
0.001015 percentage of T cells
Interval 0.0 to 0.004355
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.000810 percentage of T cells
Interval 0.0 to 0.00231
|
0.013923 percentage of T cells
Interval 0.00294 to 0.052
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.001000 percentage of T cells
Interval 0.0 to 0.005
|
0.000100 percentage of T cells
Interval 0.0 to 0.00198
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.002835 percentage of T cells
Interval 0.0 to 0.009205
|
0.002915 percentage of T cells
Interval 0.0 to 0.00873
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2
|
0.000420 percentage of T cells
Interval 0.0 to 0.002115
|
0.000100 percentage of T cells
Interval 0.0 to 0.00198
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2
|
0.000210 percentage of T cells
Interval 0.0 to 0.001285
|
0.003625 percentage of T cells
Interval 0.00166 to 0.007235
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2
|
0.000150 percentage of T cells
Interval 0.0 to 0.0015
|
0.002915 percentage of T cells
Interval 0.0 to 0.00873
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.0015
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.000000 percentage of T cells
Interval 0.0 to 0.00318
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.0085
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.039
|
0.000000 percentage of T cells
Interval 0.0 to 0.00105
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.009500 percentage of T cells
Interval 0.0 to 0.055
|
0.001295 percentage of T cells
Interval 0.0 to 0.01715
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.029500 percentage of T cells
Interval 0.0 to 0.105
|
0.003000 percentage of T cells
Interval 0.0 to 0.01715
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.002450 percentage of T cells
Interval 0.0 to 0.00536
|
0.000000 percentage of T cells
Interval 0.0 to 0.00107
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.000696 percentage of T cells
Interval 0.0 to 0.00625
|
0.000950 percentage of T cells
Interval 0.0 to 0.00403
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.002510 percentage of T cells
Interval 0.0 to 0.00648
|
0.000856 percentage of T cells
Interval 0.0 to 0.00524
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.000999
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.001574
|
0.006290 percentage of T cells
Interval 0.00093 to 0.02207
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.000090 percentage of T cells
Interval 0.0 to 0.00198
|
0.007770 percentage of T cells
Interval 0.001 to 0.04002
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.001670 percentage of T cells
Interval 0.0 to 0.00555
|
0.000000 percentage of T cells
Interval 0.0 to 0.000873
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00131
|
0.002340 percentage of T cells
Interval 0.0 to 0.00626
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3
|
0.000180 percentage of T cells
Interval 0.0 to 0.00163
|
0.002380 percentage of T cells
Interval 0.0 to 0.01
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.002000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.003000 percentage of T cells
Interval 0.0 to 0.016
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.020000 percentage of T cells
Interval 0.0 to 0.06
|
0.005000 percentage of T cells
Interval 0.0 to 0.017
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.008260 percentage of T cells
Interval 0.00305 to 0.02
|
0.001350 percentage of T cells
Interval 0.0 to 0.00819
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.005110 percentage of T cells
Interval 0.001953 to 0.01
|
0.020000 percentage of T cells
Interval 0.00258 to 0.03935
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.005380 percentage of T cells
Interval 0.00243 to 0.00942
|
0.015580 percentage of T cells
Interval 0.003084 to 0.043
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00135
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00013
|
0.001210 percentage of T cells
Interval 0.0 to 0.003
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00012
|
0.001610 percentage of T cells
Interval 0.0 to 0.00437
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.003720 percentage of T cells
Interval 0.00058 to 0.00677
|
0.018180 percentage of T cells
Interval 0.00019 to 0.054
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.002810 percentage of T cells
Interval 0.00013 to 0.00642
|
0.140000 percentage of T cells
Interval 0.058 to 0.4481
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.002890 percentage of T cells
Interval 0.00002 to 0.00624
|
0.140790 percentage of T cells
Interval 0.02894 to 0.382
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.002310 percentage of T cells
Interval 0.0 to 0.00708
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.002110 percentage of T cells
Interval 0.0 to 0.00729
|
0.000000 percentage of T cells
Interval 0.0 to 0.00076
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.003350 percentage of T cells
Interval 0.0 to 0.00836
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30
|
0.000850 percentage of T cells
Interval 0.0 to 0.00419
|
0.007490 percentage of T cells
Interval 0.00215 to 0.03258
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00289
|
0.061520 percentage of T cells
Interval 0.02526 to 0.20858
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30
|
0.000498 percentage of T cells
Interval 0.0 to 0.00352
|
0.063490 percentage of T cells
Interval 0.02 to 0.22223
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.001000 percentage of T cells
Interval 0.0 to 0.009
|
0.002000 percentage of T cells
Interval 0.0 to 0.008
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.001700 percentage of T cells
Interval 0.0 to 0.01
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.010000 percentage of T cells
Interval 0.0 to 0.04
|
0.012000 percentage of T cells
Interval 0.0 to 0.03
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.010000 percentage of T cells
Interval 0.0 to 0.05
|
0.008000 percentage of T cells
Interval 0.0 to 0.03
|
—
|
—
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.003825 percentage of T cells
Interval 0.001215 to 0.00913
|
0.000000 percentage of T cells
Interval 0.0 to 0.004075
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: ICS Subset 'by country based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.
The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=33 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=46 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
n=33 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
n=46 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.002700 percentage of T cells
Interval 0.001651 to 0.0069
|
0.006810 percentage of T cells
Interval 0.00204 to 0.01104
|
0.014500 percentage of T cells
Interval 0.002155 to 0.036
|
0.021000 percentage of T cells
Interval 0.00449 to 0.04026
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00181
|
0.000000 percentage of T cells
Interval 0.0 to 0.00085
|
0.000000 percentage of T cells
Interval 0.0 to 0.000545
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.003935 percentage of T cells
Interval 0.000208 to 0.00673
|
0.003720 percentage of T cells
Interval 0.00074 to 0.00882
|
0.024675 percentage of T cells
Interval 0.00053 to 0.14458
|
0.014000 percentage of T cells
Interval 0.00019 to 0.03033
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.001820 percentage of T cells
Interval 0.0 to 0.004055
|
0.004222 percentage of T cells
Interval 0.0 to 0.00947
|
0.000000 percentage of T cells
Interval 0.0 to 0.00009
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.003000 percentage of T cells
Interval 0.0 to 0.0095
|
0.003350 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30
|
0.000620 percentage of T cells
Interval 0.0 to 0.003105
|
0.000498 percentage of T cells
Interval 0.0 to 0.00355
|
0.074245 percentage of T cells
Interval 0.0215 to 0.19091
|
0.053520 percentage of T cells
Interval 0.014 to 0.23098
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00269
|
0.000515 percentage of T cells
Interval 0.0 to 0.00179
|
0.000000 percentage of T cells
Interval 0.0 to 0.00132
|
0.000837 percentage of T cells
Interval 0.0 to 0.00192
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00181
|
0.001120 percentage of T cells
Interval 0.0 to 0.00365
|
0.077000 percentage of T cells
Interval 0.01563 to 0.1587
|
0.067000 percentage of T cells
Interval 0.02102 to 0.155
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00168
|
0.000000 percentage of T cells
Interval 0.0 to 0.000742
|
0.018000 percentage of T cells
Interval 0.001 to 0.06376
|
0.037000 percentage of T cells
Interval 0.01137 to 0.080257
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00229
|
0.000000 percentage of T cells
Interval 0.0 to 0.000949
|
0.020970 percentage of T cells
Interval 0.003 to 0.059
|
0.021940 percentage of T cells
Interval 0.00289 to 0.03631
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.007000 percentage of T cells
Interval 0.0 to 0.011
|
0.002000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.015
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.000900 percentage of T cells
Interval 0.0 to 0.00258
|
0.001135 percentage of T cells
Interval 0.0 to 0.00218
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00167
|
0.000000 percentage of T cells
Interval 0.0 to 0.00144
|
0.000000 percentage of T cells
Interval 0.0 to 0.00192
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.002396 percentage of T cells
Interval 0.00026 to 0.005
|
0.002045 percentage of T cells
Interval 0.0 to 0.00507
|
0.011000 percentage of T cells
Interval 0.0011 to 0.06634
|
0.005500 percentage of T cells
Interval 0.0 to 0.019
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.003580 percentage of T cells
Interval 0.0 to 0.008
|
0.003275 percentage of T cells
Interval 0.0 to 0.01066
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00125
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.000205 percentage of T cells
Interval 0.0 to 0.00283
|
0.022820 percentage of T cells
Interval 0.01234 to 0.058
|
0.018425 percentage of T cells
Interval 0.00413 to 0.06056
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.010000 percentage of T cells
Interval 0.0 to 0.015
|
0.007000 percentage of T cells
Interval 0.0 to 0.012
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.002000 percentage of T cells
Interval 0.0 to 0.017
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.001000 percentage of T cells
Interval 0.0 to 0.02
|
0.002000 percentage of T cells
Interval 0.0 to 0.03
|
0.004000 percentage of T cells
Interval 0.0 to 0.017
|
0.003000 percentage of T cells
Interval 0.0 to 0.02
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.006400 percentage of T cells
Interval 0.00294 to 0.01518
|
0.005090 percentage of T cells
Interval 0.002935 to 0.0145
|
0.000000 percentage of T cells
Interval 0.0 to 0.00385
|
0.000000 percentage of T cells
Interval 0.0 to 0.002285
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.004470 percentage of T cells
Interval 0.00175 to 0.00778
|
0.001540 percentage of T cells
Interval 0.0 to 0.004138
|
0.002920 percentage of T cells
Interval 0.00002 to 0.014
|
0.005090 percentage of T cells
Interval 0.00157 to 0.009779
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.002270 percentage of T cells
Interval 0.0 to 0.00538
|
0.000740 percentage of T cells
Interval 0.0 to 0.002175
|
0.073630 percentage of T cells
Interval 0.033 to 0.14
|
0.099370 percentage of T cells
Interval 0.034095 to 0.273535
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0054
|
0.000660 percentage of T cells
Interval 0.0 to 0.00463
|
0.000000 percentage of T cells
Interval 0.0 to 0.00116
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00278
|
0.000000 percentage of T cells
Interval 0.0 to 0.002015
|
0.004600 percentage of T cells
Interval 0.0 to 0.011
|
0.001669 percentage of T cells
Interval 0.0 to 0.00781
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00276
|
0.000002 percentage of T cells
Interval 0.0 to 0.001615
|
0.015000 percentage of T cells
Interval 0.00457 to 0.02828
|
0.016169 percentage of T cells
Interval 0.00167 to 0.04781
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00355
|
0.000000 percentage of T cells
Interval 0.0 to 0.001285
|
0.018200 percentage of T cells
Interval 0.00624 to 0.035
|
0.009090 percentage of T cells
Interval 0.00003 to 0.02506
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.001000 percentage of T cells
Interval 0.0 to 0.00762
|
0.002000 percentage of T cells
Interval 0.0 to 0.009
|
0.000500 percentage of T cells
Interval 0.0 to 0.00568
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.002825 percentage of T cells
Interval 0.0 to 0.0087
|
0.004303 percentage of T cells
Interval 0.0 to 0.00726
|
0.000000 percentage of T cells
Interval 0.0 to 0.00172
|
0.000000 percentage of T cells
Interval 0.0 to 0.00116
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.001835 percentage of T cells
Interval 0.0 to 0.00699
|
0.002138 percentage of T cells
Interval 0.0 to 0.00478
|
0.001970 percentage of T cells
Interval 0.000005 to 0.00461
|
0.000000 percentage of T cells
Interval 0.0 to 0.003536
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.001486 percentage of T cells
Interval 0.0 to 0.004375
|
0.000538 percentage of T cells
Interval 0.0 to 0.00678
|
0.004090 percentage of T cells
Interval 0.0 to 0.01082
|
0.000935 percentage of T cells
Interval 0.0 to 0.00423
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.000004 percentage of T cells
Interval 0.0 to 0.00213
|
0.001599 percentage of T cells
Interval 0.00001 to 0.00581
|
0.001650 percentage of T cells
Interval 0.0 to 0.02593
|
0.000000 percentage of T cells
Interval 0.0 to 0.00179
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.001065 percentage of T cells
Interval 0.0 to 0.001825
|
0.000766 percentage of T cells
Interval 0.0 to 0.00375
|
0.045815 percentage of T cells
Interval 0.009695 to 0.09441
|
0.009520 percentage of T cells
Interval 0.0 to 0.03613
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
0.003000 percentage of T cells
Interval 0.0 to 0.00862
|
0.000000 percentage of T cells
Interval 0.0 to 0.000035
|
0.000000 percentage of T cells
Interval 0.0 to 0.00137
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1
|
0.000477 percentage of T cells
Interval 0.0 to 0.002413
|
0.000788 percentage of T cells
Interval 0.0 to 0.00267
|
0.002995 percentage of T cells
Interval 0.0 to 0.009535
|
0.000000 percentage of T cells
Interval 0.0 to 0.00321
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.001311
|
0.000000 percentage of T cells
Interval 0.0 to 0.00225
|
0.004390 percentage of T cells
Interval 0.00109 to 0.012525
|
0.002250 percentage of T cells
Interval 0.0 to 0.00891
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.001000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.004175
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.0235
|
0.025500 percentage of T cells
Interval 0.0 to 0.1
|
0.003500 percentage of T cells
Interval 0.0 to 0.0125
|
0.010500 percentage of T cells
Interval 0.0 to 0.026
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.006500 percentage of T cells
Interval 0.0 to 0.085
|
0.075000 percentage of T cells
Interval 0.0 to 0.18
|
0.005500 percentage of T cells
Interval 0.0 to 0.01821
|
0.010000 percentage of T cells
Interval 0.0 to 0.022
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.003832 percentage of T cells
Interval 0.001292 to 0.007035
|
0.002406 percentage of T cells
Interval 0.0 to 0.00689
|
0.000000 percentage of T cells
Interval 0.0 to 0.00105
|
0.000000 percentage of T cells
Interval 0.0 to 0.000998
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000631 percentage of T cells
Interval 0.0 to 0.005337
|
0.000000 percentage of T cells
Interval 0.0 to 0.000743
|
0.000000 percentage of T cells
Interval 0.0 to 0.000988
|
0.000000 percentage of T cells
Interval 0.0 to 0.000982
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.000261 percentage of T cells
Interval 0.0 to 0.00136
|
0.001095 percentage of T cells
Interval 0.0 to 0.002335
|
0.002010 percentage of T cells
Interval 0.000025 to 0.004425
|
0.000000 percentage of T cells
Interval 0.0 to 0.00429
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.000413 percentage of T cells
Interval 0.0 to 0.001012
|
0.000050 percentage of T cells
Interval 0.0 to 0.00247
|
0.012063 percentage of T cells
Interval 0.00312 to 0.045755
|
0.015970 percentage of T cells
Interval 0.00681 to 0.069945
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.000895 percentage of T cells
Interval 0.0 to 0.003615
|
0.001000 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.000535
|
0.000000 percentage of T cells
Interval 0.0 to 0.000054
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.00206
|
0.000380 percentage of T cells
Interval 0.0 to 0.003775
|
0.000000 percentage of T cells
Interval 0.0 to 0.000927
|
0.000000 percentage of T cells
Interval 0.0 to 0.000908
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2
|
0.001005 percentage of T cells
Interval 0.0 to 0.001785
|
0.000050 percentage of T cells
Interval 0.0 to 0.001196
|
0.004335 percentage of T cells
Interval 0.002185 to 0.00814
|
0.003555 percentage of T cells
Interval 0.00085 to 0.0072
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.0005
|
0.000000 percentage of T cells
Interval 0.0 to 0.0035
|
0.000000 percentage of T cells
Interval 0.0 to 0.006325
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.0035
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.002180 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.0015
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.0305
|
0.020000 percentage of T cells
Interval 0.0 to 0.07
|
0.004155 percentage of T cells
Interval 0.0 to 0.01315
|
0.001295 percentage of T cells
Interval 0.0 to 0.0195
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.000500 percentage of T cells
Interval 0.0 to 0.065
|
0.047000 percentage of T cells
Interval 0.0055 to 0.11
|
0.001370 percentage of T cells
Interval 0.0 to 0.01365
|
0.003500 percentage of T cells
Interval 0.0 to 0.02
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.001810 percentage of T cells
Interval 0.0 to 0.007589
|
0.002624 percentage of T cells
Interval 0.0 to 0.00501
|
0.000000 percentage of T cells
Interval 0.0 to 0.00103
|
0.000000 percentage of T cells
Interval 0.0 to 0.00124
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.001000 percentage of T cells
Interval 0.0 to 0.003
|
0.001000 percentage of T cells
Interval 0.0 to 0.00268
|
0.000000 percentage of T cells
Interval 0.0 to 0.00109
|
0.000000 percentage of T cells
Interval 0.0 to 0.000813
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3
|
0.000025 percentage of T cells
Interval 0.0 to 0.00163
|
0.000000 percentage of T cells
Interval 0.0 to 0.00131
|
0.001680 percentage of T cells
Interval 0.0 to 0.007
|
0.002390 percentage of T cells
Interval 0.0 to 0.00626
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.021500 percentage of T cells
Interval 0.0 to 0.05
|
0.020000 percentage of T cells
Interval 0.0 to 0.09
|
0.008500 percentage of T cells
Interval 0.0 to 0.017
|
0.004000 percentage of T cells
Interval 0.0 to 0.015
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.005000 percentage of T cells
Interval 0.0 to 0.012145
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.002000 percentage of T cells
Interval 0.0 to 0.0105
|
0.001620 percentage of T cells
Interval 0.0 to 0.008
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.005670 percentage of T cells
Interval 0.00112 to 0.017245
|
0.010590 percentage of T cells
Interval 0.00488 to 0.02
|
0.001655 percentage of T cells
Interval 0.0 to 0.0235
|
0.001350 percentage of T cells
Interval 0.0 to 0.00472
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.003892 percentage of T cells
Interval 0.00196 to 0.00776
|
0.005450 percentage of T cells
Interval 0.00316 to 0.012
|
0.021000 percentage of T cells
Interval 0.002955 to 0.0395
|
0.014000 percentage of T cells
Interval 0.003084 to 0.049
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.000865
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.001170 percentage of T cells
Interval 0.0 to 0.00299
|
0.001210 percentage of T cells
Interval 0.0 to 0.00334
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.001013
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.001825 percentage of T cells
Interval 0.0 to 0.004
|
0.001490 percentage of T cells
Interval 0.0 to 0.00464
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.002880 percentage of T cells
Interval 0.000202 to 0.004855
|
0.002710 percentage of T cells
Interval 0.00013 to 0.00667
|
0.114125 percentage of T cells
Interval 0.034725 to 0.40257
|
0.172000 percentage of T cells
Interval 0.06572 to 0.5883
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.003100 percentage of T cells
Interval 0.000195 to 0.006109
|
0.002890 percentage of T cells
Interval 0.00001 to 0.00634
|
0.129260 percentage of T cells
Interval 0.037645 to 0.34477
|
0.142870 percentage of T cells
Interval 0.02618 to 0.39
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.002110 percentage of T cells
Interval 0.0 to 0.009815
|
0.001700 percentage of T cells
Interval 0.0 to 0.00661
|
0.000000 percentage of T cells
Interval 0.0 to 0.001004
|
0.000000 percentage of T cells
Interval 0.0 to 0.00018
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30
|
0.001440 percentage of T cells
Interval 0.0 to 0.00483
|
0.000850 percentage of T cells
Interval 0.0 to 0.00326
|
0.019265 percentage of T cells
Interval 0.0042 to 0.078745
|
0.006850 percentage of T cells
Interval 0.00085 to 0.01534
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30
|
0.001240 percentage of T cells
Interval 0.0 to 0.002885
|
0.000000 percentage of T cells
Interval 0.0 to 0.00316
|
0.065510 percentage of T cells
Interval 0.02563 to 0.16284
|
0.061520 percentage of T cells
Interval 0.02454 to 0.28778
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000500 percentage of T cells
Interval 0.0 to 0.011645
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.008590 percentage of T cells
Interval 0.0 to 0.0175
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.007000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.03
|
0.004000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.004500 percentage of T cells
Interval 0.0 to 0.0255
|
0.010000 percentage of T cells
Interval 0.0 to 0.048
|
0.008500 percentage of T cells
Interval 0.003 to 0.019
|
0.014000 percentage of T cells
Interval 0.0 to 0.04
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.04
|
0.020000 percentage of T cells
Interval 0.0 to 0.05
|
0.009000 percentage of T cells
Interval 0.0 to 0.0245
|
0.002000 percentage of T cells
Interval 0.0 to 0.035
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.001485 percentage of T cells
Interval 0.0 to 0.00603
|
0.005670 percentage of T cells
Interval 0.00237 to 0.01037
|
0.000000 percentage of T cells
Interval 0.0 to 0.00207
|
0.001030 percentage of T cells
Interval 0.0 to 0.00485
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.002448 percentage of T cells
Interval 0.0 to 0.00703
|
0.003491 percentage of T cells
Interval 0.00071 to 0.00629
|
0.003364 percentage of T cells
Interval 0.0 to 0.00612
|
0.008860 percentage of T cells
Interval 0.00311 to 0.016
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.001415 percentage of T cells
Interval 0.0 to 0.0056
|
0.003270 percentage of T cells
Interval 0.000791 to 0.00578
|
0.003560 percentage of T cells
Interval 0.00122 to 0.00874
|
0.005580 percentage of T cells
Interval 0.00057 to 0.01777
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000100 percentage of T cells
Interval 0.0 to 0.00213
|
0.000679 percentage of T cells
Interval 0.0 to 0.0013
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.000722
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00136
|
0.000000 percentage of T cells
Interval 0.0 to 0.000921
|
0.000000 percentage of T cells
Interval 0.0 to 0.00168
|
0.001175 percentage of T cells
Interval 0.0 to 0.00345
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.000545 percentage of T cells
Interval 0.0 to 0.00274
|
0.001290 percentage of T cells
Interval 0.0 to 0.00287
|
0.003760 percentage of T cells
Interval 0.0 to 0.042
|
0.005470 percentage of T cells
Interval 0.000662 to 0.019
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.000645 percentage of T cells
Interval 0.0 to 0.00269
|
0.002120 percentage of T cells
Interval 0.0 to 0.00377
|
0.047980 percentage of T cells
Interval 0.02729 to 0.15468
|
0.125320 percentage of T cells
Interval 0.05882 to 0.21381
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00101
|
0.004140 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00095
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.000793 percentage of T cells
Interval 0.0 to 0.003
|
0.001000 percentage of T cells
Interval 0.0 to 0.00423
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.00000 percentage of T cells
Interval 0.0 to 0.000791
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.001000 percentage of T cells
Interval 0.0 to 0.003
|
0.004530 percentage of T cells
Interval 0.00122 to 0.008
|
0.00000 percentage of T cells
Interval 0.0 to 0.0
|
0.00000 percentage of T cells
Interval 0.0 to 0.000725
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.001955 percentage of T cells
Interval 0.0 to 0.0066
|
0.000000 percentage of T cells
Interval 0.0 to 0.00135
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00212
|
0.000000 percentage of T cells
Interval 0.0 to 0.000968
|
0.003210 percentage of T cells
Interval 0.0 to 0.019
|
0.001540 percentage of T cells
Interval 0.0 to 0.00478
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.002000 percentage of T cells
Interval 0.0 to 0.011
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.004000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
0.001000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.0015
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.00795
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.005000 percentage of T cells
Interval 0.0 to 0.021
|
0.000000 percentage of T cells
Interval 0.0 to 0.015
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.029
|
0.005500 percentage of T cells
Interval 0.0 to 0.0385
|
0.016000 percentage of T cells
Interval 0.0 to 0.04
|
0.010000 percentage of T cells
Interval 0.0 to 0.053
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.05
|
0.000000 percentage of T cells
Interval 0.0 to 0.04
|
0.021000 percentage of T cells
Interval 0.0 to 0.045
|
0.010000 percentage of T cells
Interval 0.0 to 0.029
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000758 percentage of T cells
Interval 0.0 to 0.002335
|
0.000000 percentage of T cells
Interval 0.0 to 0.00159
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000035 percentage of T cells
Interval 0.0 to 0.00169
|
0.000000 percentage of T cells
Interval 0.0 to 0.00114
|
0.000000 percentage of T cells
Interval 0.0 to 0.000918
|
0.000000 percentage of T cells
Interval 0.0 to 0.00114
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00123
|
0.000000 percentage of T cells
Interval 0.0 to 0.00162
|
0.000000 percentage of T cells
Interval 0.0 to 0.00095
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.001170 percentage of T cells
Interval 0.0 to 0.00205
|
0.000965 percentage of T cells
Interval 0.0 to 0.00334
|
0.022915 percentage of T cells
Interval 0.008465 to 0.0465
|
0.022820 percentage of T cells
Interval 0.004 to 0.06195
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.002758 percentage of T cells
Interval 0.0 to 0.007
|
0.003735 percentage of T cells
Interval 0.0 to 0.01182
|
0.000000 percentage of T cells
Interval 0.0 to 0.00101
|
0.000000 percentage of T cells
Interval 0.0 to 0.00159
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.001053 percentage of T cells
Interval 0.0 to 0.006
|
0.004910 percentage of T cells
Interval 0.00006 to 0.014
|
0.000000 percentage of T cells
Interval 0.0 to 0.001315
|
0.000795 percentage of T cells
Interval 0.0 to 0.00151
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1
|
0.000456 percentage of T cells
Interval 0.0 to 0.00279
|
0.000000 percentage of T cells
Interval 0.0 to 0.00144
|
0.008865 percentage of T cells
Interval 0.00251 to 0.019285
|
0.000465 percentage of T cells
Interval 0.0 to 0.00639
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.002000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.00944
|
0.000500 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.05
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.019
|
0.000000 percentage of T cells
Interval 0.0 to 0.036
|
0.004000 percentage of T cells
Interval 0.0 to 0.022
|
0.020000 percentage of T cells
Interval 0.002 to 0.042
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.03
|
0.026000 percentage of T cells
Interval 0.0 to 0.06
|
0.005000 percentage of T cells
Interval 0.0 to 0.017
|
0.010000 percentage of T cells
Interval 0.0 to 0.03
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.005531 percentage of T cells
Interval 0.00334 to 0.01278
|
0.009230 percentage of T cells
Interval 0.00386 to 0.01861
|
0.001590 percentage of T cells
Interval 0.0 to 0.00691
|
0.001100 percentage of T cells
Interval 0.0 to 0.00258
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.0145
|
0.005000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.01394
|
0.000500 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.021
|
0.020000 percentage of T cells
Interval 0.0 to 0.13
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
0.000895 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.002690 percentage of T cells
Interval 0.001041 to 0.00719
|
0.003495 percentage of T cells
Interval 0.00142 to 0.00666
|
0.010000 percentage of T cells
Interval 0.00285 to 0.016
|
0.010000 percentage of T cells
Interval 0.00265 to 0.019
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.000661 percentage of T cells
Interval 0.0 to 0.00299
|
0.002598 percentage of T cells
Interval 0.0 to 0.00547
|
0.013000 percentage of T cells
Interval 0.00483 to 0.021
|
0.006905 percentage of T cells
Interval 0.00118 to 0.028
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00119
|
0.000000 percentage of T cells
Interval 0.0 to 0.00165
|
0.001175 percentage of T cells
Interval 0.0 to 0.00345
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.002456 percentage of T cells
Interval 0.00025 to 0.00598
|
0.001800 percentage of T cells
Interval 0.0 to 0.0032
|
0.092920 percentage of T cells
Interval 0.03825 to 0.16
|
0.153500 percentage of T cells
Interval 0.04852 to 0.35317
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.001452 percentage of T cells
Interval 0.000337 to 0.005767
|
0.000503 percentage of T cells
Interval 0.0 to 0.002644
|
0.002230 percentage of T cells
Interval 0.000484 to 0.002745
|
0.001875 percentage of T cells
Interval 0.0 to 0.00479
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.002005 percentage of T cells
Interval 0.000323 to 0.00771
|
0.001335 percentage of T cells
Interval 0.0 to 0.005545
|
0.002595 percentage of T cells
Interval 0.00129 to 0.005245
|
0.000812 percentage of T cells
Interval 0.0 to 0.00574
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.001005 percentage of T cells
Interval 0.0 to 0.00225
|
0.000000 percentage of T cells
Interval 0.0 to 0.000797
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.001590 percentage of T cells
Interval 0.0 to 0.002636
|
0.000702 percentage of T cells
Interval 0.0 to 0.00296
|
0.094740 percentage of T cells
Interval 0.03005 to 0.205
|
0.096615 percentage of T cells
Interval 0.03158 to 0.22
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.005710 percentage of T cells
Interval 0.0 to 0.01
|
0.008335 percentage of T cells
Interval 0.0029 to 0.017
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000982 percentage of T cells
Interval 0.0 to 0.00276
|
0.000000 percentage of T cells
Interval 0.0 to 0.000007
|
0.000000 percentage of T cells
Interval 0.0 to 0.001062
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.00552
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120
|
0.002490 percentage of T cells
Interval 0.0 to 0.00556
|
0.001520 percentage of T cells
Interval 0.0 to 0.00438
|
0.006000 percentage of T cells
Interval 0.00177 to 0.019
|
0.003750 percentage of T cells
Interval 0.0 to 0.00724
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120
|
0.001620 percentage of T cells
Interval 0.0 to 0.00263
|
0.000365 percentage of T cells
Interval 0.0 to 0.002
|
0.033420 percentage of T cells
Interval 0.009 to 0.08186
|
0.039000 percentage of T cells
Interval 0.015 to 0.10485
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.001500 percentage of T cells
Interval 0.0 to 0.011
|
0.005000 percentage of T cells
Interval 0.0 to 0.017
|
0.000000 percentage of T cells
Interval 0.0 to 0.012
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.001000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.005000 percentage of T cells
Interval 0.0 to 0.015
|
0.000000 percentage of T cells
Interval 0.0 to 0.014
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.000656 percentage of T cells
Interval 0.0 to 0.00171
|
0.001055 percentage of T cells
Interval 0.0 to 0.00322
|
0.018930 percentage of T cells
Interval 0.00816 to 0.050495
|
0.009770 percentage of T cells
Interval 0.00216 to 0.054
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.001555 percentage of T cells
Interval 0.0 to 0.008615
|
0.003865 percentage of T cells
Interval 0.0 to 0.009705
|
0.000000 percentage of T cells
Interval 0.0 to 0.000856
|
0.000000 percentage of T cells
Interval 0.0 to 0.000963
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2
|
0.000702 percentage of T cells
Interval 0.0 to 0.002704
|
0.000020 percentage of T cells
Interval 0.0 to 0.00169
|
0.000860 percentage of T cells
Interval 0.0 to 0.001435
|
0.000030 percentage of T cells
Interval 0.0 to 0.00208
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2
|
0.000985 percentage of T cells
Interval 0.0 to 0.00182
|
0.000085 percentage of T cells
Interval 0.0 to 0.001405
|
0.005735 percentage of T cells
Interval 0.00278 to 0.0168
|
0.001155 percentage of T cells
Interval 0.0 to 0.00758
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.03
|
0.000000 percentage of T cells
Interval 0.0 to 0.028
|
0.010000 percentage of T cells
Interval 0.0 to 0.02
|
0.016500 percentage of T cells
Interval 0.0 to 0.033
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.020000 percentage of T cells
Interval 0.0 to 0.05
|
0.015000 percentage of T cells
Interval 0.0 to 0.049
|
0.013000 percentage of T cells
Interval 0.0 to 0.02734
|
0.011000 percentage of T cells
Interval 0.0 to 0.031
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.002890 percentage of T cells
Interval 0.00191 to 0.00453
|
0.002393 percentage of T cells
Interval 0.0 to 0.005765
|
0.006040 percentage of T cells
Interval 0.00112 to 0.03078
|
0.003620 percentage of T cells
Interval 0.000478 to 0.01416
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00149
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0021
|
0.000000 percentage of T cells
Interval 0.0 to 0.000915
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00122
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00122
|
0.000000 percentage of T cells
Interval 0.0 to 0.00155
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.000200 percentage of T cells
Interval 0.0 to 0.00227
|
0.001386 percentage of T cells
Interval 0.0 to 0.003795
|
0.004620 percentage of T cells
Interval 0.00127 to 0.04145
|
0.004695 percentage of T cells
Interval 0.0 to 0.0195
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00187
|
0.000430 percentage of T cells
Interval 0.0 to 0.002875
|
0.093000 percentage of T cells
Interval 0.02209 to 0.19796
|
0.056525 percentage of T cells
Interval 0.01744 to 0.183385
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000500 percentage of T cells
Interval 0.0 to 0.022
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.004385
|
0.000000 percentage of T cells
Interval 0.0 to 0.0095
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.002000 percentage of T cells
Interval 0.0 to 0.012
|
0.005400 percentage of T cells
Interval 0.001685 to 0.00978
|
0.000000 percentage of T cells
Interval 0.0 to 0.00066
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.003500 percentage of T cells
Interval 0.0 to 0.0445
|
0.000000 percentage of T cells
Interval 0.0 to 0.00287
|
0.000000 percentage of T cells
Interval 0.0 to 0.001
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3
|
0.000012 percentage of T cells
Interval 0.0 to 0.00182
|
0.000584 percentage of T cells
Interval 0.0 to 0.00156
|
0.002050 percentage of T cells
Interval 0.0 to 0.01336
|
0.002380 percentage of T cells
Interval 0.000857 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.000530 percentage of T cells
Interval 0.0 to 0.003668
|
0.000760 percentage of T cells
Interval 0.0 to 0.00752
|
0.000985 percentage of T cells
Interval 0.0 to 0.00403
|
0.000844 percentage of T cells
Interval 0.0 to 0.0065
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.001915 percentage of T cells
Interval 0.0 to 0.00697
|
0.002884 percentage of T cells
Interval 0.0 to 0.00648
|
0.001735 percentage of T cells
Interval 0.0 to 0.00633
|
0.000000 percentage of T cells
Interval 0.0 to 0.00269
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.000819
|
0.000000 percentage of T cells
Interval 0.0 to 0.001137
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.001238
|
0.000080 percentage of T cells
Interval 0.0 to 0.00166
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.000763
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.001265 percentage of T cells
Interval 0.0 to 0.00371
|
0.000000 percentage of T cells
Interval 0.0 to 0.00199
|
0.000000 percentage of T cells
Interval 0.0 to 0.00115
|
0.000000 percentage of T cells
Interval 0.0 to 0.000905
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000070 percentage of T cells
Interval 0.0 to 0.00184
|
0.000540 percentage of T cells
Interval 0.0 to 0.00241
|
0.001065 percentage of T cells
Interval 0.0 to 0.00676
|
0.000000 percentage of T cells
Interval 0.0 to 0.00214
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00114
|
0.000000 percentage of T cells
Interval 0.0 to 0.0018
|
0.007670 percentage of T cells
Interval 0.002 to 0.016
|
0.005610 percentage of T cells
Interval 0.0006 to 0.02543
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00112
|
0.001050 percentage of T cells
Interval 0.0 to 0.00294
|
0.011465 percentage of T cells
Interval 0.0 to 0.04506
|
0.005570 percentage of T cells
Interval 0.001 to 0.028163
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.001695 percentage of T cells
Interval 0.0 to 0.00432
|
0.001650 percentage of T cells
Interval 0.0 to 0.00557
|
0.000000 percentage of T cells
Interval 0.0 to 0.001013
|
0.000000 percentage of T cells
Interval 0.0 to 0.000873
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.002695 percentage of T cells
Interval 0.0 to 0.006
|
0.001330 percentage of T cells
Interval 0.0 to 0.00933
|
0.000000 percentage of T cells
Interval 0.0 to 0.00147
|
0.000000 percentage of T cells
Interval 0.0 to 0.000617
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.001219
|
0.000300 percentage of T cells
Interval 0.0 to 0.00163
|
0.001048 percentage of T cells
Interval 0.0 to 0.00268
|
0.000000 percentage of T cells
Interval 0.0 to 0.00195
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.001000 percentage of T cells
Interval 0.0 to 0.011
|
0.001000 percentage of T cells
Interval 0.0 to 0.019
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.002000 percentage of T cells
Interval 0.0 to 0.02
|
0.002000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.001000 percentage of T cells
Interval 0.0 to 0.007
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.016
|
0.000500 percentage of T cells
Interval 0.0 to 0.01171
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
|
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.001000 percentage of T cells
Interval 0.0 to 0.009
|
0.008000 percentage of T cells
Interval 0.0 to 0.022
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3Population: ICS Subset 'by Baseline seropositivity status based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed=participants with data available for analysis for specific category.
The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) \>=10 for one or more dengue serotypes. Seronegative was defined as titer value of \<10 for all 4 serotypes. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=44 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
n=35 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
n=44 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
n=35 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.0013
|
0.000000 percentage of T cells
Interval 0.0 to 0.001475
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.001650 percentage of T cells
Interval 0.0 to 0.00417
|
0.000190 percentage of T cells
Interval 0.0 to 0.002215
|
0.003430 percentage of T cells
Interval 0.0 to 0.019
|
0.008115 percentage of T cells
Interval 0.00003 to 0.024475
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.001470 percentage of T cells
Interval 0.0 to 0.0036
|
0.000803 percentage of T cells
Interval 0.0 to 0.00325
|
0.099000 percentage of T cells
Interval 0.036 to 0.289
|
0.069910 percentage of T cells
Interval 0.027 to 0.1765
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00224
|
0.000798 percentage of T cells
Interval 0.0 to 0.002785
|
0.070000 percentage of T cells
Interval 0.029 to 0.258
|
0.055015 percentage of T cells
Interval 0.016265 to 0.12852
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.003230 percentage of T cells
Interval 0.0 to 0.00919
|
0.005735 percentage of T cells
Interval 0.00113 to 0.01352
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00492
|
0.000515 percentage of T cells
Interval 0.0 to 0.00463
|
0.000000 percentage of T cells
Interval 0.0 to 0.000055
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.001000 percentage of T cells
Interval 0.0 to 0.00347
|
0.002470 percentage of T cells
Interval 0.0 to 0.007075
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00147
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0028
|
0.000000 percentage of T cells
Interval 0.0 to 0.001245
|
0.003060 percentage of T cells
Interval 0.0 to 0.00845
|
0.003350 percentage of T cells
Interval 0.0 to 0.008815
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270
|
0.000330 percentage of T cells
Interval 0.0 to 0.00255
|
0.000000 percentage of T cells
Interval 0.0 to 0.00139
|
0.022120 percentage of T cells
Interval 0.00296 to 0.03208
|
0.007160 percentage of T cells
Interval 0.002385 to 0.016904
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00316
|
0.000000 percentage of T cells
Interval 0.0 to 0.002085
|
0.015270 percentage of T cells
Interval 0.00062 to 0.03383
|
0.008945 percentage of T cells
Interval 0.002924 to 0.02728
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.001500 percentage of T cells
Interval 0.0 to 0.0105
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.001000 percentage of T cells
Interval 0.0 to 0.0085
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.001
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.0035
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.0075
|
0.000000 percentage of T cells
Interval 0.0 to 0.00746
|
0.000000 percentage of T cells
Interval 0.0 to 0.0055
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.003000 percentage of T cells
Interval 0.0 to 0.029
|
0.000000 percentage of T cells
Interval 0.0 to 0.015
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270
|
0.019000 percentage of T cells
Interval 0.0 to 0.05
|
0.000000 percentage of T cells
Interval 0.0 to 0.0115
|
0.026000 percentage of T cells
Interval 0.006 to 0.07
|
0.004000 percentage of T cells
Interval 0.0 to 0.0285
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270
|
0.009000 percentage of T cells
Interval 0.0 to 0.05
|
0.000000 percentage of T cells
Interval 0.0 to 0.027
|
0.015000 percentage of T cells
Interval 0.004 to 0.047
|
0.006000 percentage of T cells
Interval 0.0 to 0.0245
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.006710 percentage of T cells
Interval 0.00162 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.00437
|
0.000000 percentage of T cells
Interval 0.0 to 0.00231
|
0.000000 percentage of T cells
Interval 0.0 to 0.00087
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.002960 percentage of T cells
Interval 0.0 to 0.00698
|
0.001590 percentage of T cells
Interval 0.0 to 0.00405
|
0.000170 percentage of T cells
Interval 0.0 to 0.00502
|
0.002000 percentage of T cells
Interval 0.0 to 0.00342
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.003220 percentage of T cells
Interval 0.0 to 0.00755
|
0.000000 percentage of T cells
Interval 0.0 to 0.002285
|
0.002460 percentage of T cells
Interval 0.0 to 0.01
|
0.001200 percentage of T cells
Interval 0.0 to 0.00426
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000745 percentage of T cells
Interval 0.0 to 0.0017
|
0.000000 percentage of T cells
Interval 0.0 to 0.00218
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00124
|
0.000000 percentage of T cells
Interval 0.0 to 0.00151
|
0.000000 percentage of T cells
Interval 0.0 to 0.00133
|
0.000000 percentage of T cells
Interval 0.0 to 0.00006
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.00162
|
0.000000 percentage of T cells
Interval 0.0 to 0.000789
|
0.000000 percentage of T cells
Interval 0.0 to 0.000961
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.001110 percentage of T cells
Interval 0.0 to 0.00418
|
0.000920 percentage of T cells
Interval 0.0 to 0.00231
|
0.000000 percentage of T cells
Interval 0.0 to 0.015
|
0.000000 percentage of T cells
Interval 0.0 to 0.00775
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.001430 percentage of T cells
Interval 0.00024 to 0.002718
|
0.000170 percentage of T cells
Interval 0.0 to 0.00281
|
0.033910 percentage of T cells
Interval 0.00779 to 0.06195
|
0.013000 percentage of T cells
Interval 0.004 to 0.03849
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.001058 percentage of T cells
Interval 0.0 to 0.00326
|
0.000522 percentage of T cells
Interval 0.0 to 0.00276
|
0.036130 percentage of T cells
Interval 0.00645 to 0.12615
|
0.010120 percentage of T cells
Interval 0.00103 to 0.04
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1
|
0.003000 percentage of T cells
Interval 0.0 to 0.01182
|
0.003000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.00126
|
0.000000 percentage of T cells
Interval 0.0 to 0.00102
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1
|
0.003000 percentage of T cells
Interval 0.0 to 0.00682
|
0.001000 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.000794
|
0.000000 percentage of T cells
Interval 0.0 to 0.00113
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1
|
0.002000 percentage of T cells
Interval 0.0 to 0.011
|
0.004000 percentage of T cells
Interval 0.0 to 0.012
|
0.000000 percentage of T cells
Interval 0.0 to 0.00168
|
0.000000 percentage of T cells
Interval 0.0 to 0.00133
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1
|
0.000190 percentage of T cells
Interval 0.0 to 0.00258
|
0.000746 percentage of T cells
Interval 0.0 to 0.00267
|
0.000000 percentage of T cells
Interval 0.0 to 0.00688
|
0.001300 percentage of T cells
Interval 0.0 to 0.0052
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.001802
|
0.000000 percentage of T cells
Interval 0.0 to 0.00243
|
0.003000 percentage of T cells
Interval 0.0 to 0.012095
|
0.003150 percentage of T cells
Interval 0.0 to 0.00926
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1
|
0.000070 percentage of T cells
Interval 0.0 to 0.00188
|
0.000000 percentage of T cells
Interval 0.0 to 0.0019
|
0.003000 percentage of T cells
Interval 0.0 to 0.0251
|
0.003800 percentage of T cells
Interval 0.0 to 0.012
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.002000 percentage of T cells
Interval 0.0 to 0.015
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.018
|
0.006000 percentage of T cells
Interval 0.0 to 0.02
|
0.001000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.06
|
0.020000 percentage of T cells
Interval 0.0 to 0.06
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1
|
0.000000 percentage of T cells
Interval 0.0 to 0.09
|
0.010000 percentage of T cells
Interval 0.0 to 0.06
|
0.006000 percentage of T cells
Interval 0.0 to 0.024
|
0.004420 percentage of T cells
Interval 0.0 to 0.017
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1
|
0.057000 percentage of T cells
Interval 0.0 to 0.1
|
0.034000 percentage of T cells
Interval 0.0 to 0.14
|
0.007000 percentage of T cells
Interval 0.0 to 0.031
|
0.007000 percentage of T cells
Interval 0.0 to 0.01742
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.003744 percentage of T cells
Interval 0.00187 to 0.009
|
0.001200 percentage of T cells
Interval 0.0 to 0.00392
|
0.000000 percentage of T cells
Interval 0.0 to 0.00104
|
0.000000 percentage of T cells
Interval 0.0 to 0.0011
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.000613 percentage of T cells
Interval 0.0 to 0.004954
|
0.000860 percentage of T cells
Interval 0.0 to 0.002303
|
0.002100 percentage of T cells
Interval 0.000786 to 0.00489
|
0.000042 percentage of T cells
Interval 0.0 to 0.00295
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.001490 percentage of T cells
Interval 0.0 to 0.00399
|
0.001510 percentage of T cells
Interval 0.00005 to 0.00587
|
0.001700 percentage of T cells
Interval 0.0 to 0.00517
|
0.001340 percentage of T cells
Interval 0.0 to 0.00532
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.00182
|
0.000000 percentage of T cells
Interval 0.0 to 0.000948
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.000751
|
0.000000 percentage of T cells
Interval 0.0 to 0.000954
|
0.000000 percentage of T cells
Interval 0.0 to 0.00003
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.00217
|
0.000000 percentage of T cells
Interval 0.0 to 0.000803
|
0.000000 percentage of T cells
Interval 0.0 to 0.000953
|
0.000000 percentage of T cells
Interval 0.0 to 0.00119
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.001190 percentage of T cells
Interval 0.000045 to 0.00181
|
0.000120 percentage of T cells
Interval 0.0 to 0.00264
|
0.001720 percentage of T cells
Interval 0.0 to 0.00628
|
0.000000 percentage of T cells
Interval 0.0 to 0.00257
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.00195
|
0.000150 percentage of T cells
Interval 0.0 to 0.000948
|
0.025000 percentage of T cells
Interval 0.00899 to 0.06724
|
0.007800 percentage of T cells
Interval 0.00264 to 0.04641
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.000631 percentage of T cells
Interval 0.0 to 0.00221
|
0.001390 percentage of T cells
Interval 0.0 to 0.00241
|
0.015650 percentage of T cells
Interval 0.00288 to 0.054
|
0.012220 percentage of T cells
Interval 0.00348 to 0.02882
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2
|
0.001000 percentage of T cells
Interval 0.0 to 0.005
|
0.000380 percentage of T cells
Interval 0.0 to 0.00351
|
0.000000 percentage of T cells
Interval 0.0 to 0.000835
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2
|
0.000760 percentage of T cells
Interval 0.0 to 0.00667
|
0.000000 percentage of T cells
Interval 0.0 to 0.00307
|
0.000000 percentage of T cells
Interval 0.0 to 0.000852
|
0.000000 percentage of T cells
Interval 0.0 to 0.00113
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2
|
0.002000 percentage of T cells
Interval 0.0 to 0.00876
|
0.005000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.00094
|
0.000000 percentage of T cells
Interval 0.0 to 0.000947
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2
|
0.000320 percentage of T cells
Interval 0.0 to 0.00213
|
0.000588 percentage of T cells
Interval 0.0 to 0.0021
|
0.000670 percentage of T cells
Interval 0.0 to 0.00194
|
0.000000 percentage of T cells
Interval 0.0 to 0.00202
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2
|
0.000180 percentage of T cells
Interval 0.0 to 0.00113
|
0.000578 percentage of T cells
Interval 0.0 to 0.00168
|
0.004920 percentage of T cells
Interval 0.002 to 0.00737
|
0.003380 percentage of T cells
Interval 0.00013 to 0.00703
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2
|
0.000621 percentage of T cells
Interval 0.0 to 0.001449
|
0.000017 percentage of T cells
Interval 0.0 to 0.00155
|
0.004580 percentage of T cells
Interval 0.0 to 0.00915
|
0.001140 percentage of T cells
Interval 0.0 to 0.00721
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.000000 percentage of T cells
Interval 0.0 to 0.002
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.016
|
0.000000 percentage of T cells
Interval 0.0 to 0.00536
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2
|
0.000000 percentage of T cells
Interval 0.0 to 0.049
|
0.000000 percentage of T cells
Interval 0.0 to 0.022
|
0.000000 percentage of T cells
Interval 0.0 to 0.00464
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2
|
0.011000 percentage of T cells
Interval 0.0 to 0.05
|
0.006000 percentage of T cells
Interval 0.0 to 0.06
|
0.008310 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.014
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2
|
0.044000 percentage of T cells
Interval 0.001 to 0.1
|
0.018000 percentage of T cells
Interval 0.0 to 0.11
|
0.004000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.0143
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.003110 percentage of T cells
Interval 0.0 to 0.008297
|
0.001934 percentage of T cells
Interval 0.00018 to 0.00429
|
0.000000 percentage of T cells
Interval 0.0 to 0.00107
|
0.000000 percentage of T cells
Interval 0.0 to 0.00146
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.000645 percentage of T cells
Interval 0.0 to 0.007
|
0.000760 percentage of T cells
Interval 0.0 to 0.00625
|
0.000060 percentage of T cells
Interval 0.0 to 0.00305
|
0.001830 percentage of T cells
Interval 0.0 to 0.00409
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.002612 percentage of T cells
Interval 0.0 to 0.0073
|
0.002510 percentage of T cells
Interval 0.0 to 0.0038
|
0.001420 percentage of T cells
Interval 0.0 to 0.00633
|
0.000000 percentage of T cells
Interval 0.0 to 0.00269
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.000831
|
0.000000 percentage of T cells
Interval 0.0 to 0.00118
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00124
|
0.000778 percentage of T cells
Interval 0.0 to 0.00167
|
0.000000 percentage of T cells
Interval 0.0 to 0.000811
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.000686 percentage of T cells
Interval 0.0 to 0.00277
|
0.000000 percentage of T cells
Interval 0.0 to 0.00207
|
0.000000 percentage of T cells
Interval 0.0 to 0.00129
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000070 percentage of T cells
Interval 0.0 to 0.00207
|
0.000557 percentage of T cells
Interval 0.0 to 0.00194
|
0.000000 percentage of T cells
Interval 0.0 to 0.00304
|
0.000000 percentage of T cells
Interval 0.0 to 0.00256
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00166
|
0.000000 percentage of T cells
Interval 0.0 to 0.001574
|
0.012470 percentage of T cells
Interval 0.002 to 0.023163
|
0.004220 percentage of T cells
Interval 0.00021 to 0.0149
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.00158
|
0.001050 percentage of T cells
Interval 0.0 to 0.002364
|
0.007735 percentage of T cells
Interval 0.001 to 0.05336
|
0.007770 percentage of T cells
Interval 0.000832 to 0.029
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3
|
0.001740 percentage of T cells
Interval 0.0 to 0.00557
|
0.001650 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.000873
|
0.000000 percentage of T cells
Interval 0.0 to 0.00093
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3
|
0.000880 percentage of T cells
Interval 0.0 to 0.00268
|
0.001000 percentage of T cells
Interval 0.0 to 0.00381
|
0.000000 percentage of T cells
Interval 0.0 to 0.00075
|
0.000000 percentage of T cells
Interval 0.0 to 0.00189
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3
|
0.001500 percentage of T cells
Interval 0.0 to 0.00817
|
0.002170 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.00123
|
0.000000 percentage of T cells
Interval 0.0 to 0.00015
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.000702
|
0.000864 percentage of T cells
Interval 0.0 to 0.002005
|
0.000000 percentage of T cells
Interval 0.0 to 0.00182
|
0.000090 percentage of T cells
Interval 0.0 to 0.00268
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.001637
|
0.000000 percentage of T cells
Interval 0.0 to 0.00131
|
0.002707 percentage of T cells
Interval 0.0 to 0.00656
|
0.002320 percentage of T cells
Interval 0.0 to 0.00626
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3
|
0.000523 percentage of T cells
Interval 0.0 to 0.00182
|
0.000010 percentage of T cells
Interval 0.0 to 0.00156
|
0.002955 percentage of T cells
Interval 0.0 to 0.01125
|
0.001070 percentage of T cells
Interval 0.0 to 0.00667
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000040 percentage of T cells
Interval 0.0 to 0.005
|
0.000000 percentage of T cells
Interval 0.0 to 0.003
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.003000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.00483
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3
|
0.000500 percentage of T cells
Interval 0.0 to 0.015
|
0.004000 percentage of T cells
Interval 0.0 to 0.013
|
0.000500 percentage of T cells
Interval 0.0 to 0.007
|
0.000000 percentage of T cells
Interval 0.0 to 0.006
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.03
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000000 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.01171
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.000000 percentage of T cells
Interval 0.0 to 0.012
|
0.004000 percentage of T cells
Interval 0.0 to 0.014
|
0.001270 percentage of T cells
Interval 0.0 to 0.026
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3
|
0.023000 percentage of T cells
Interval 0.0 to 0.06
|
0.016000 percentage of T cells
Interval 0.0 to 0.07
|
0.003000 percentage of T cells
Interval 0.0 to 0.016
|
0.008000 percentage of T cells
Interval 0.0 to 0.018
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.013000 percentage of T cells
Interval 0.00482 to 0.023
|
0.007655 percentage of T cells
Interval 0.001679 to 0.011295
|
0.002170 percentage of T cells
Interval 0.0 to 0.0076
|
0.000245 percentage of T cells
Interval 0.0 to 0.009595
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.005140 percentage of T cells
Interval 0.00196 to 0.014
|
0.004985 percentage of T cells
Interval 0.001651 to 0.008985
|
0.021000 percentage of T cells
Interval 0.00254 to 0.03935
|
0.017000 percentage of T cells
Interval 0.003855 to 0.0385
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.005380 percentage of T cells
Interval 0.00241 to 0.012
|
0.005255 percentage of T cells
Interval 0.00266 to 0.00903
|
0.018000 percentage of T cells
Interval 0.00238 to 0.05
|
0.009560 percentage of T cells
Interval 0.003965 to 0.0285
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00106
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00334
|
0.001330 percentage of T cells
Interval 0.0 to 0.00299
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0011
|
0.001540 percentage of T cells
Interval 0.0 to 0.00416
|
0.001695 percentage of T cells
Interval 0.0 to 0.00499
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.004740 percentage of T cells
Interval 0.00093 to 0.008483
|
0.003070 percentage of T cells
Interval 0.000398 to 0.00592
|
0.018190 percentage of T cells
Interval 0.0 to 0.06647
|
0.015540 percentage of T cells
Interval 0.0015 to 0.051595
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.002710 percentage of T cells
Interval 0.0 to 0.00675
|
0.002885 percentage of T cells
Interval 0.000779 to 0.00504
|
0.108250 percentage of T cells
Interval 0.05223 to 0.49
|
0.168175 percentage of T cells
Interval 0.06327 to 0.431355
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.002630 percentage of T cells
Interval 0.00107 to 0.00553
|
0.003785 percentage of T cells
Interval 0.0 to 0.007035
|
0.150000 percentage of T cells
Interval 0.034 to 0.307
|
0.117545 percentage of T cells
Interval 0.02756 to 0.49045
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30
|
0.003620 percentage of T cells
Interval 0.0 to 0.011
|
0.002275 percentage of T cells
Interval 0.0 to 0.00607
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.000008
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30
|
0.002150 percentage of T cells
Interval 0.0 to 0.008
|
0.001230 percentage of T cells
Interval 0.0 to 0.004635
|
0.000000 percentage of T cells
Interval 0.0 to 0.00031
|
0.000000 percentage of T cells
Interval 0.0 to 0.001035
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30
|
0.003720 percentage of T cells
Interval 0.0 to 0.00761
|
0.002270 percentage of T cells
Interval 0.0 to 0.009435
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.000488
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30
|
0.000850 percentage of T cells
Interval 0.0 to 0.00364
|
0.000835 percentage of T cells
Interval 0.0 to 0.004635
|
0.007750 percentage of T cells
Interval 0.00215 to 0.035143
|
0.007370 percentage of T cells
Interval 0.002315 to 0.03029
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.00316
|
0.000065 percentage of T cells
Interval 0.0 to 0.00245
|
0.065380 percentage of T cells
Interval 0.01347 to 0.17
|
0.051500 percentage of T cells
Interval 0.02985 to 0.23891
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30
|
0.000280 percentage of T cells
Interval 0.0 to 0.00294
|
0.000900 percentage of T cells
Interval 0.0 to 0.00404
|
0.053520 percentage of T cells
Interval 0.022 to 0.11602
|
0.101275 percentage of T cells
Interval 0.01746 to 0.23476
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30
|
0.001000 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.00959
|
0.002000 percentage of T cells
Interval 0.0 to 0.008
|
0.002000 percentage of T cells
Interval 0.0 to 0.0095
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.0035
|
0.000000 percentage of T cells
Interval 0.0 to 0.00773
|
0.000000 percentage of T cells
Interval 0.0 to 0.00811
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.000500 percentage of T cells
Interval 0.0 to 0.00909
|
0.000000 percentage of T cells
Interval 0.0 to 0.01
|
0.003610 percentage of T cells
Interval 0.0 to 0.0095
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30
|
0.003000 percentage of T cells
Interval 0.0 to 0.03
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.005000 percentage of T cells
Interval 0.0 to 0.018
|
0.000000 percentage of T cells
Interval 0.0 to 0.0045
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30
|
0.010000 percentage of T cells
Interval 0.0 to 0.045
|
0.001500 percentage of T cells
Interval 0.0 to 0.03
|
0.018000 percentage of T cells
Interval 0.003 to 0.035
|
0.006000 percentage of T cells
Interval 0.0 to 0.02
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30
|
0.028000 percentage of T cells
Interval 0.0 to 0.07
|
0.000000 percentage of T cells
Interval 0.0 to 0.031
|
0.015000 percentage of T cells
Interval 0.0 to 0.032
|
0.000000 percentage of T cells
Interval 0.0 to 0.0245
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.005720 percentage of T cells
Interval 0.002968 to 0.01069
|
0.002190 percentage of T cells
Interval 0.00102 to 0.00603
|
0.000013 percentage of T cells
Interval 0.0 to 0.0043
|
0.000000 percentage of T cells
Interval 0.0 to 0.00298
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.003592 percentage of T cells
Interval 0.000811 to 0.00736
|
0.001325 percentage of T cells
Interval 0.0 to 0.00582
|
0.004660 percentage of T cells
Interval 0.00144 to 0.01377
|
0.005880 percentage of T cells
Interval 0.0016 to 0.00886
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.002795 percentage of T cells
Interval 0.0 to 0.0069
|
0.001420 percentage of T cells
Interval 0.0 to 0.00553
|
0.003260 percentage of T cells
Interval 0.0 to 0.014
|
0.004563 percentage of T cells
Interval 0.00149 to 0.00901
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000842 percentage of T cells
Interval 0.0 to 0.00196
|
0.000000 percentage of T cells
Interval 0.0 to 0.000888
|
0.000000 percentage of T cells
Interval 0.0 to 0.000722
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.000544 percentage of T cells
Interval 0.0 to 0.00251
|
0.000000 percentage of T cells
Interval 0.0 to 0.000824
|
0.000785 percentage of T cells
Interval 0.0 to 0.00256
|
0.000000 percentage of T cells
Interval 0.0 to 0.001132
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.000921
|
0.000000 percentage of T cells
Interval 0.0 to 0.001039
|
0.000383 percentage of T cells
Interval 0.0 to 0.00162
|
0.000000 percentage of T cells
Interval 0.0 to 0.00205
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.001540 percentage of T cells
Interval 0.0 to 0.003473
|
0.000490 percentage of T cells
Interval 0.0 to 0.00137
|
0.002893 percentage of T cells
Interval 0.00004 to 0.019
|
0.006540 percentage of T cells
Interval 0.0 to 0.02466
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.001583 percentage of T cells
Interval 0.0 to 0.00305
|
0.001810 percentage of T cells
Interval 0.0 to 0.00306
|
0.103350 percentage of T cells
Interval 0.034 to 0.21381
|
0.107000 percentage of T cells
Interval 0.031 to 0.17862
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.001090 percentage of T cells
Interval 0.0 to 0.003265
|
0.000410 percentage of T cells
Interval 0.0 to 0.00246
|
0.081000 percentage of T cells
Interval 0.01211 to 0.129362
|
0.069105 percentage of T cells
Interval 0.01934 to 0.192
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90
|
0.001245 percentage of T cells
Interval 0.0 to 0.00785
|
0.001050 percentage of T cells
Interval 0.0 to 0.009
|
0.000000 percentage of T cells
Interval 0.0 to 0.000912
|
0.000000 percentage of T cells
Interval 0.0 to 0.00065
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00277
|
0.001880 percentage of T cells
Interval 0.0 to 0.004
|
0.000000 percentage of T cells
Interval 0.0 to 0.000791
|
0.000000 percentage of T cells
Interval 0.0 to 0.00003
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90
|
0.003980 percentage of T cells
Interval 0.0 to 0.00633
|
0.002055 percentage of T cells
Interval 0.0 to 0.00537
|
0.000000 percentage of T cells
Interval 0.0 to 0.000022
|
0.000000 percentage of T cells
Interval 0.0 to 0.000725
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90
|
0.000010 percentage of T cells
Interval 0.0 to 0.00183
|
0.000000 percentage of T cells
Interval 0.0 to 0.00108
|
0.002390 percentage of T cells
Interval 0.0 to 0.00694
|
0.001535 percentage of T cells
Interval 0.0 to 0.00531
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00107
|
0.000000 percentage of T cells
Interval 0.0 to 0.00086
|
0.039000 percentage of T cells
Interval 0.00995 to 0.096152
|
0.017000 percentage of T cells
Interval 0.00624 to 0.043
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.00152
|
0.000000 percentage of T cells
Interval 0.0 to 0.000949
|
0.026425 percentage of T cells
Interval 0.00225 to 0.059
|
0.015420 percentage of T cells
Interval 0.00449 to 0.04161
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.000500 percentage of T cells
Interval 0.0 to 0.008
|
0.002000 percentage of T cells
Interval 0.0 to 0.006
|
0.000500 percentage of T cells
Interval 0.0 to 0.012
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.002000 percentage of T cells
Interval 0.0 to 0.01
|
0.000500 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90
|
0.001500 percentage of T cells
Interval 0.0 to 0.01
|
0.006500 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.009
|
0.001000 percentage of T cells
Interval 0.0 to 0.011
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.02
|
0.000000 percentage of T cells
Interval 0.0 to 0.008
|
0.000000 percentage of T cells
Interval 0.0 to 0.012
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.036
|
0.001000 percentage of T cells
Interval 0.0 to 0.02
|
0.008405 percentage of T cells
Interval 0.001 to 0.038
|
0.018000 percentage of T cells
Interval 0.0 to 0.032
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90
|
0.000000 percentage of T cells
Interval 0.0 to 0.05
|
0.010405 percentage of T cells
Interval 0.0 to 0.05
|
0.005450 percentage of T cells
Interval 0.0 to 0.027
|
0.009500 percentage of T cells
Interval 0.0 to 0.026
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.011000 percentage of T cells
Interval 0.00386 to 0.017
|
0.005531 percentage of T cells
Interval 0.00334 to 0.01601
|
0.001400 percentage of T cells
Interval 0.0 to 0.00403
|
0.001320 percentage of T cells
Interval 0.0 to 0.00424
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.003480 percentage of T cells
Interval 0.0 to 0.00883
|
0.003300 percentage of T cells
Interval 0.00167 to 0.00551
|
0.010000 percentage of T cells
Interval 0.00265 to 0.028
|
0.010000 percentage of T cells
Interval 0.00274 to 0.015
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.002705 percentage of T cells
Interval 0.0 to 0.00547
|
0.001460 percentage of T cells
Interval 0.0 to 0.003
|
0.012000 percentage of T cells
Interval 0.00267 to 0.035
|
0.006000 percentage of T cells
Interval 0.00223 to 0.013
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.000975 percentage of T cells
Interval 0.0 to 0.00267
|
0.001220 percentage of T cells
Interval 0.0 to 0.00184
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.00158
|
0.000000 percentage of T cells
Interval 0.0 to 0.00115
|
0.000000 percentage of T cells
Interval 0.0 to 0.00192
|
0.000000 percentage of T cells
Interval 0.0 to 0.00146
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.000908
|
0.000000 percentage of T cells
Interval 0.0 to 0.000953
|
0.001540 percentage of T cells
Interval 0.0 to 0.00345
|
0.000000 percentage of T cells
Interval 0.0 to 0.00165
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.002885 percentage of T cells
Interval 0.00076 to 0.00532
|
0.002070 percentage of T cells
Interval 0.0 to 0.00368
|
0.007155 percentage of T cells
Interval 0.0 to 0.036
|
0.007850 percentage of T cells
Interval 0.0 to 0.028
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.002915 percentage of T cells
Interval 0.00109 to 0.00437
|
0.000450 percentage of T cells
Interval 0.0 to 0.00267
|
0.144565 percentage of T cells
Interval 0.03911 to 0.447
|
0.093000 percentage of T cells
Interval 0.05341 to 0.16327
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.000702 percentage of T cells
Interval 0.0 to 0.00369
|
0.001570 percentage of T cells
Interval 0.0 to 0.00215
|
0.102525 percentage of T cells
Interval 0.03988 to 0.29121
|
0.078900 percentage of T cells
Interval 0.02519 to 0.1344
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120
|
0.004735 percentage of T cells
Interval 0.00028 to 0.013
|
0.011430 percentage of T cells
Interval 0.00391 to 0.017
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120
|
0.000530 percentage of T cells
Interval 0.0 to 0.00552
|
0.000000 percentage of T cells
Interval 0.0 to 0.00373
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00114
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120
|
0.003100 percentage of T cells
Interval 0.0 to 0.007
|
0.006490 percentage of T cells
Interval 0.0 to 0.01066
|
0.000000 percentage of T cells
Interval 0.0 to 0.00142
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120
|
0.001520 percentage of T cells
Interval 0.0 to 0.00471
|
0.002490 percentage of T cells
Interval 0.0 to 0.00503
|
0.004280 percentage of T cells
Interval 0.00106 to 0.00927
|
0.004080 percentage of T cells
Interval 0.0 to 0.01679
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120
|
0.001235 percentage of T cells
Interval 0.0 to 0.00248
|
0.000190 percentage of T cells
Interval 0.0 to 0.00272
|
0.046825 percentage of T cells
Interval 0.015 to 0.11121
|
0.024000 percentage of T cells
Interval 0.007 to 0.05611
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120
|
0.000020 percentage of T cells
Interval 0.0 to 0.00248
|
0.000000 percentage of T cells
Interval 0.0 to 0.00226
|
0.034610 percentage of T cells
Interval 0.011 to 0.10121
|
0.016280 percentage of T cells
Interval 0.00648 to 0.03063
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120
|
0.009500 percentage of T cells
Interval 0.0 to 0.011
|
0.006000 percentage of T cells
Interval 0.0 to 0.015
|
0.001500 percentage of T cells
Interval 0.0 to 0.017
|
0.002000 percentage of T cells
Interval 0.0 to 0.014
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.007
|
0.002000 percentage of T cells
Interval 0.0 to 0.011
|
0.000500 percentage of T cells
Interval 0.0 to 0.019
|
0.003000 percentage of T cells
Interval 0.0 to 0.012
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.013
|
0.000000 percentage of T cells
Interval 0.0 to 0.011
|
0.006000 percentage of T cells
Interval 0.0 to 0.02
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120
|
0.007000 percentage of T cells
Interval 0.0 to 0.04
|
0.000000 percentage of T cells
Interval 0.0 to 0.019
|
0.004500 percentage of T cells
Interval 0.0 to 0.028
|
0.000000 percentage of T cells
Interval 0.0 to 0.014
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120
|
0.008000 percentage of T cells
Interval 0.0 to 0.03
|
0.000000 percentage of T cells
Interval 0.0 to 0.028
|
0.018000 percentage of T cells
Interval 0.0 to 0.034
|
0.009000 percentage of T cells
Interval 0.0 to 0.019
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120
|
0.020000 percentage of T cells
Interval 0.0 to 0.05
|
0.010000 percentage of T cells
Interval 0.0 to 0.04
|
0.016500 percentage of T cells
Interval 0.0 to 0.04
|
0.008000 percentage of T cells
Interval 0.0 to 0.02305
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270
|
0.008790 percentage of T cells
Interval 0.00297 to 0.019
|
0.004355 percentage of T cells
Interval 0.00262 to 0.01189
|
0.000000 percentage of T cells
Interval 0.0 to 0.00276
|
0.000411 percentage of T cells
Interval 0.0 to 0.00242
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270
|
0.003410 percentage of T cells
Interval 0.0 to 0.00681
|
0.002170 percentage of T cells
Interval 0.000355 to 0.004995
|
0.008760 percentage of T cells
Interval 0.00236 to 0.02
|
0.002605 percentage of T cells
Interval 0.00001 to 0.008395
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270
|
0.002890 percentage of T cells
Interval 0.00111 to 0.00516
|
0.002720 percentage of T cells
Interval 0.000059 to 0.00548
|
0.003960 percentage of T cells
Interval 0.00112 to 0.026
|
0.004575 percentage of T cells
Interval 0.0 to 0.01242
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.00098
|
0.000000 percentage of T cells
Interval 0.0 to 0.000505
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.00193
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
|
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270
|
0.000000 percentage of T cells
Interval 0.0 to 0.0
|
0.000000 percentage of T cells
Interval 0.0 to 0.000635
|
0.000000 percentage of T cells
Interval 0.0 to 0.00157
|
0.000000 percentage of T cells
Interval 0.0 to 0.00115
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=195 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Year 3
|
125.2 titer
Interval 92.8 to 169.0
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Year 3
|
546.4 titer
Interval 435.2 to 686.0
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Year 3
|
91.6 titer
Interval 69.4 to 120.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Day 30
|
402.3 titer
Interval 287.5 to 562.9
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Day 30
|
5482.2 titer
Interval 4626.4 to 6496.3
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Day 30
|
436.1 titer
Interval 326.9 to 581.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Day 30
|
253.9 titer
Interval 182.6 to 353.1
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Day 90
|
271.7 titer
Interval 193.9 to 380.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Day 90
|
2736.3 titer
Interval 2295.1 to 3262.5
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Day 90
|
218.7 titer
Interval 162.0 to 295.2
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Day 90
|
177.4 titer
Interval 129.6 to 242.8
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Day 120
|
550.6 titer
Interval 408.0 to 743.1
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Day 120
|
2808.2 titer
Interval 2395.0 to 3292.8
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Day 120
|
404.2 titer
Interval 312.6 to 522.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Day 120
|
427.1 titer
Interval 335.4 to 543.8
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Day 270
|
343.3 titer
Interval 249.8 to 471.6
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Day 270
|
1729.9 titer
Interval 1435.7 to 2084.4
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Day 270
|
203.8 titer
Interval 153.5 to 270.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Day 270
|
186.6 titer
Interval 141.6 to 246.0
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Year 1
|
243.8 titer
Interval 176.4 to 337.0
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Year 1
|
896.2 titer
Interval 729.9 to 1100.5
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Year 1
|
148.6 titer
Interval 111.6 to 197.7
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Year 1
|
142.4 titer
Interval 108.8 to 186.3
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Year 2
|
290.8 titer
Interval 200.8 to 421.1
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-2, Year 2
|
724.7 titer
Interval 564.2 to 930.8
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-3, Year 2
|
172.7 titer
Interval 120.6 to 247.1
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-4, Year 2
|
157.7 titer
Interval 114.0 to 218.0
|
—
|
—
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
DENV-1, Year 3
|
178.7 titer
Interval 127.3 to 250.8
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.
Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=195 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Year 3
|
86.1 percentage of participants
Interval 80.2 to 90.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Day 30
|
96.8 percentage of participants
Interval 93.1 to 98.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Day 30
|
99.5 percentage of participants
Interval 97.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Day 30
|
99.5 percentage of participants
Interval 97.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Day 30
|
93.0 percentage of participants
Interval 88.3 to 96.2
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Day 90
|
90.8 percentage of participants
Interval 85.8 to 94.4
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Day 90
|
99.5 percentage of participants
Interval 97.2 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Day 90
|
94.4 percentage of participants
Interval 90.1 to 97.2
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Day 90
|
91.8 percentage of participants
Interval 87.0 to 95.2
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Day 120
|
99.5 percentage of participants
Interval 97.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Day 120
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Day 120
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Day 120
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Day 270
|
96.8 percentage of participants
Interval 93.1 to 98.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Day 270
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Day 270
|
97.9 percentage of participants
Interval 94.6 to 99.4
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Day 270
|
96.8 percentage of participants
Interval 93.1 to 98.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Year 1
|
91.1 percentage of participants
Interval 86.2 to 94.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Year 1
|
100.0 percentage of participants
Interval 98.1 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Year 1
|
93.8 percentage of participants
Interval 89.3 to 96.7
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Year 1
|
96.4 percentage of participants
Interval 92.6 to 98.5
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Year 2
|
93.5 percentage of participants
Interval 88.4 to 96.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Year 2
|
100.0 percentage of participants
Interval 97.6 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Year 2
|
89.6 percentage of participants
Interval 83.7 to 93.9
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-4, Year 2
|
95.5 percentage of participants
Interval 90.9 to 98.2
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-1, Year 3
|
84.4 percentage of participants
Interval 78.3 to 89.4
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-2, Year 3
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
DENV-3, Year 3
|
86.7 percentage of participants
Interval 80.8 to 91.3
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.
Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=195 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Day 30
|
90.8 percentage of participants
Interval 85.7 to 94.6
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Day 30
|
98.4 percentage of participants
Interval 95.3 to 99.7
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Day 90
|
83.6 percentage of participants
Interval 77.6 to 88.5
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Day 90
|
95.4 percentage of participants
Interval 91.4 to 97.9
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Day 120
|
99.5 percentage of participants
Interval 97.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Day 120
|
100.0 percentage of participants
Interval 98.0 to 100.0
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Day 270
|
93.0 percentage of participants
Interval 88.4 to 96.2
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Day 270
|
98.4 percentage of participants
Interval 95.4 to 99.7
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Year 1
|
87.5 percentage of participants
Interval 82.0 to 91.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Year 1
|
95.3 percentage of participants
Interval 91.3 to 97.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Year 2
|
86.4 percentage of participants
Interval 79.9 to 91.4
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Year 2
|
93.5 percentage of participants
Interval 88.4 to 96.8
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
Tetravalent, Year 3
|
76.7 percentage of participants
Interval 69.8 to 82.6
|
—
|
—
|
—
|
|
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
At Least Trivalent, Year 3
|
87.2 percentage of participants
Interval 81.4 to 91.7
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]Population: Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analyzed is the number of participants with data available for analysis at the given timepoint.
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants Experiencing Unsolicited Adverse Events (AE)
After First Vaccination
|
26.5 percentage of participants
|
—
|
—
|
—
|
|
Percentage of Participants Experiencing Unsolicited Adverse Events (AE)
After Second Vaccination
|
25.3 percentage of participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.
MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Medically Attended AEs (MAAEs)
|
50.5 percentage of participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first vaccination (Day 1) up to end of study (Approximately 3 years)Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.
A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Serious Adverse Events (SAEs)
|
5.5 percentage of participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.
Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).
Outcome measures
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 Participants
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.
|
TDV 0.5 mL: Panama: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.
|
TDV 0.5 ml: Philippines: CD8+ T Cells
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.
|
|---|---|---|---|---|
|
Percentage of Participants With Virologically Confirmed Dengue
|
6.0 percentage of participants
|
—
|
—
|
—
|
Adverse Events
Tetravalent Dengue Vaccine (TDV) 0.5 mL
Serious events: 11 serious events
Other events: 66 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 participants at risk
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
|---|---|
|
Infections and infestations
Cellulitis
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Pneumonia
|
1.5%
3/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Typhoid fever
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Urosepsis
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Gastrointestinal disorders
Faecaloma
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Gastrointestinal disorders
Gastritis
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Hepatobiliary disorders
Biliary colic
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Dengue fever
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Gastroenteritis
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Systemic viral infection
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Nervous system disorders
Febrile convulsion
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Social circumstances
Victim of sexual abuse
|
0.50%
1/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
Other adverse events
| Measure |
Tetravalent Dengue Vaccine (TDV) 0.5 mL
n=200 participants at risk
TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).
|
|---|---|
|
Infections and infestations
Nasopharyngitis
|
14.5%
29/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Upper respiratory tract infection
|
10.0%
20/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Gastroenteritis
|
6.0%
12/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Systemic viral infection
|
4.5%
9/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Pneumonia
|
4.0%
8/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
|
Infections and infestations
Conjunctivitis
|
2.0%
4/200 • All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to end of study (Approximately 3 years); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
- Publication restrictions are in place
Restriction type: OTHER